From WikiProjectMed
Jump to navigation Jump to search

Combination of
DoravirineNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Trade namesDelstrigo
Other namesDoravirine/lamivudine/tenofovir disoproxil fumarate, MK-1439A
Clinical data
Main usesHIV/AIDS[1]
Side effectsDizziness, nausea, abnormal dreams[1]
External links
License data
Legal status

Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a combination medication used to treat HIV/AIDS.[1] It may be used as an initial treatment.[1] It may be the only medication a person requires.[1] It is taken by mouth.[1]

Common side effects include dizziness, nausea, and abnormal dreams.[1] Other side effects may include kidney problems, osteoporosis, and immune reconstitution syndrome.[1] Safety in pregnancy is unclear.[4] It contains doravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), and lamivudine and tenofovir disoproxil, both nucleoside analogue reverse transcriptase inhibitors.[1]

The combination was approved for medical use in the United States and Europe in 2018.[1][2] In the United Kingdom a month of medication costs the NHS about £580 as of 2021.[5] In Canada this amount is about 865 CAD while in the United States it is about 2,260 USD.[6][7]

Medical uses


It is taken as a dose of 1 tablet of 100 mg of doravirine, 300 mg of lamivudine, and 300 mg of tenofovir disoproxil fumarate per day.[1][2] In Europe each tablet contains 245 mg of tenofovir disoproxil.[2]


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 "Delstrigo- doravirine, lamivudine, and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 10 October 2019. Archived from the original on 1 February 2021. Retrieved 31 July 2020.
  2. 2.0 2.1 2.2 2.3 "Delstrigo EPAR". European Medicines Agency (EMA). Archived from the original on 28 October 2020. Retrieved 1 October 2020.
  3. "Delstrigo 100 mg /300 mg /245 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 8 July 2020. Archived from the original on 28 August 2021. Retrieved 1 October 2020.
  4. "Doravirine / lamivudine / tenofovir (Delstrigo) Use During Pregnancy". Archived from the original on 22 November 2021. Retrieved 27 December 2021.
  5. BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 692. ISBN 978-0857114105.
  6. Canadian Agency for Drugs and Technologies in Health (June 2019). "Common Drug Review New Combination Product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (Delstrigo)". CADTH Common Drug Reviews. Ottawa (ON). PMID 31393687. Archived from the original on 28 August 2021. Retrieved 3 May 2021.
  7. "Delstrigo Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 27 December 2021.

External links